First recipient of Tennessee’s $5M startup fund has ‘limitless’ drug potential

“The University of Tennessee Research Foundation has selected Orion Therapeutics as the first recipient of its $5 million fund to support startups that bring research from the university’s labs to the market.
Orion is developing a new way to deliver drugs that use ribonucleic acid, or RNA, to new places in the body.”
“InvestTN” announces seven new investments

“After making its first investment in November and 11 investments in the first quarter of 2024, Launch Tennessee has announced seven additional portfolio companies for the $70-million “InvestTN” fund that it manages for the State of Tennessee.”
Nanotechnology-based Drug Delivery Platforms: 5 Startups to Watch!

“The growing use of nanotechnology in drug delivery is transforming healthcare by allowing for targeted, efficient, and controlled release of medications! These young companies are great examples of startups leading the way in this transformation, developing state-of-the-art technologies that improve the precision and effectiveness of treatments!”
Orion Therapeutics Wins Golden Ticket Challenge for Lab Space at Biolabs Tufts Launch Pad

“Orion receives Golden Ticket for a year long occupancy in BioLabs supported by Chiesi. This represents a huge opportunity for Orion to extend its footprint to Boston and advance its novel delivery platform.”
Orion Therapeutics wins LSTCON “Venture Forum”

“Orion Therapeutics Inc., a Knoxville-based therapeutic company, won this year’s “Venture Forum” and a $10,000 cash prize from Holland & Knight that brought the curtain down on LSTCON, the annual Life Science Tennessee conference held Wednesday at the Westin Hotel in Nashville.”
Long-term vision and partnership: UTRF startup to develop next-generation RNA medicines using a novel drug delivery system

“Around a decade ago, a researcher at the University of Tennessee Graduate School of Medicine (UTSGM) and a graduate student in her lab began to imagine creating a company based on a technology they were developing. In 2022, their initial dream became a reality.”
MassBio’s Biotech Accelerator, MassBioDrive, Announces Fall 2022 Cohort of Startups

“The latest cohort of MassBioDrive, a key initiative of MassBio’s innovation programming designed to support entrepreneurs and startups, was announced today by MassBio and features six emerging biotechs from four U.S. states and Canada. The companies, working on a diverse range of focus areas, will learn from members of MassBio’s global life sciences network how to effectively and efficiently launch their enterprises.”